...
机译:I阶段试验:Cirmtuzumab抑制慢性淋巴细胞白血病患者的ROR1信号和茎秆签名
Moores Cancer Center University of California San Diego;
Moores Cancer Center University of California San Diego;
Moores Cancer Center University of California San Diego;
Moores Cancer Center University of California San Diego;
Moores Cancer Center University of California San Diego;
Moores Cancer Center University of California San Diego;
Moores Cancer Center University of California San Diego;
Moores Cancer Center University of California San Diego;
Moores Cancer Center University of California San Diego;
Moores Cancer Center University of California San Diego;
Moores Cancer Center University of California San Diego;
Moores Cancer Center University of California San Diego;
Moores Cancer Center University of California San Diego;
Moores Cancer Center University of California San Diego;
Moores Cancer Center University of California San Diego;
Moores Cancer Center University of California San Diego;
机译:I阶段试验:Cirmtuzumab抑制慢性淋巴细胞白血病患者的ROR1信号和茎秆签名
机译:复发性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者静脉注射Hsp90抑制剂alvespimycin(17-DMAG)的I期试验
机译:新型蛋白酶体抑制剂卡非佐米用于复发性慢性淋巴细胞白血病和小淋巴细胞淋巴瘤患者的I期剂量递增试验
机译:基于蛋白质组学的临床多激酶抑制剂诱导肾凋亡凋亡的靶碎屑(CLL)
机译:通过相间FISH检测一组B细胞慢性淋巴细胞性白血病患者中12号染色体的三体性频率和D13S319基因座的单等位基因缺失。
机译:Hsp90抑制剂alvespimycin(17-DMAG)在复发性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者中进行的I期试验
机译:I阶段试验:Cirmtuzumab抑制慢性淋巴细胞白血病患者的ROR1信号和茎秆签名